Ehrlich carcinoma is among cancer research’s oldest and most widely used experimental tumor models. It was initially isolated from murine mammary tissue in work associated with Paul Ehrlich and later developed into an ascitic form. Its practical advantages include rapid tumor establishment after subcutaneous or intraperitoneal inoculation, straightforward transplantation, reproducibility under established conditions and growth in immunocompetent hosts without extensive genetic manipulation.

Solid tumors provide a localized mass for studying angiogenesis and growth, whereas the ascitic form grows in the peritoneal cavity and permits examination of disseminated tumor cells and organism-level interactions. These properties support investigation of tumor growth, immune dysregulation, metabolic remodeling, treatment response and cancer-associated complications, but the model does not reproduce the full biology of human breast cancer. As tumor burden increases, experimental animals can develop cachexia, anemia and hepatic or renal dysfunction, with multi-organ failure as a systemic consequence.

Ehrlich carcinoma therefore offers a way to examine how malignancy changes whole-host physiology rather than only the behavior of cultured tumor cells. The review describes applications in anticancer-agent testing, immunomodulator research and metabolic-inhibitor studies. It also identifies features of aggressive tumor biology that make the model relevant to angiogenesis, inflammation, oxidative stress, therapeutic resistance and immune–metabolic remodeling.

Those features must be interpreted carefully: the experimental tumor is transplantable and relatively undifferentiated, and ascitic Ehrlich carcinoma should not be treated as a direct representation of breast cancer peritoneal metastasis. Neither solid nor ascitic disease captures the full architecture, cellular diversity, patient-specific genetics or endocrine environment of human tumors. Most historical EC/EAC research has focused on tumor inhibition, drug screening, individual biochemical markers, signaling pathways and early phenotypic outcomes.

Established areas of investigation include PI3K/AKT/mTOR, NF-κB, apoptosis, hypoxia-associated angiogenesis, inflammatory mediators and pathways associated with metabolic plasticity and drug resistance. The model has consequently supported studies of targeted therapeutics, nanomedicines, gene manipulation and therapeutic combinations. However, the review notes that many experiments cover short periods and emphasize early tumor inhibition rather than dormancy, immune adaptation, relapse, acquired resistance or delayed organ toxicity.

Variability in host strain, inoculation dose, tumor form and outcome measurement also weakens cross-study comparability. The authors therefore recommend longer studies with serial sampling, survival-based endpoints and common reporting standards for tumor burden, immune biomarkers, metabolic measures, organ toxicity and survival. The review’s most specific proposal centers on RNA-induced silencing complex, or RISC, which links microRNA expression to repression of target transcripts.

Mature microRNAs are processed by Dicer and loaded into Argonaute-containing RISC complexes, with AGO2 occupying the pathway’s functional core. Individual microRNAs have already been studied in Ehrlich carcinoma. Reported work has linked miR-125a-5p with reduced STAT3 activation and enhanced doxorubicin response following thymoquinone treatment, while miR-191-5p and miR-543 have been examined in relation to metabolic and inflammatory responses.

These findings support an involvement for small-RNA regulation, but they do not define the coordinated relationship among microRNA abundance, Dicer, Argonaute proteins, target repression and tumor phenotype. The abundance of one microRNA alone consequently cannot establish whether the silencing machinery is functionally active or whether an observed transcript change is caused by microRNA-mediated repression. A testable workflow proposed in the review would begin with comparative microRNA profiling of Ehrlich carcinoma tissue and appropriate controls, alongside measurement of AGO2, Dicer and related components at RNA and protein levels.

These data could be integrated with RNA sequencing or targeted transcriptomics to nominate candidate regulatory networks. Researchers could then use gain- and loss-of-function experiments to test selected interactions and assess proliferation, migration, invasion, apoptosis and treatment response. The central hypothesis is that altered RISC activity contributes to aggressive phenotypes by reshaping post-transcriptional control of genes involved in growth, apoptosis, epithelial–mesenchymal transition, inflammation and therapy response.

That hypothesis remains to be established. A combined small-RNA, transcriptomic, protein and functional approach would help distinguish changes in microRNA expression from changes in the activity of the silencing machinery itself. Integrated multi-omics could broaden the analysis beyond individual pathways.

The review proposes combining transcriptomic, proteomic, metabolomic, lipidomic and small-RNA measurements to identify coordinated molecular programs associated with progression, treatment response and host toxicity. Such an EC/EAC atlas has not yet been assembled, and the ascitic and solid forms have not been comprehensively compared through such an integrated framework. Coordinated profiling could reveal redundancy, immunometabolic communication and adaptive states that are difficult to infer from one molecular layer.

Epigenetic analysis is an additional priority. DNA methylation, histone modification, chromatin accessibility and higher-order chromatin structure have received comparatively little attention in this model, leaving poorly characterized the regulatory processes associated with phenotypic plasticity, immune suppression and resistance. Epigenomic mapping could therefore test whether reversible chromatin states contribute to transitions among proliferative, invasive, stem-like or drug-tolerant phenotypes.

Single-cell RNA sequencing and spatial transcriptomics could extend the analysis from bulk tissue to the cellular ecosystem. Conventional assays can conceal malignant subclones, distinct immune-cell states and local signaling niches, while ascitic tumors lack the spatial organization characteristic of solid human malignancies. High-resolution profiling could identify where regulatory signals originate and clarify relationships among tumor cells, infiltrating immune cells and stromal compartments.

Functional genomics would add causal tests to this descriptive work. Ehrlich carcinoma has been studied less with CRISPR-based tools than with pharmacological inhibitors, antioxidants or dietary interventions that can act on several targets at once. Stable knockouts, inducible knockdowns, knock-in reporters and barcoded populations could test whether specific genes contribute to growth, immune regulation, resistance or host toxicity.

The review also proposes systematic profiling of PD-1, PD-L1, CTLA-4, LAG-3, TIM-3 and TIGIT, whose expression dynamics, cellular origins and functional relevance remain incompletely characterized in the model. More exploratory directions include tumor–microbiome interactions, dynamic metabolic analysis, neuro-tumoral signaling and circadian regulation. Ehrlich carcinoma’s rapid proliferation, systemic inflammation, cachexia and immune–metabolic remodeling make these subjects accessible, but the review treats them as proposed areas for future work rather than established findings in EC/EAC.

Isotope tracing and flux analysis could examine how tumor and host cells reallocate nutrients during hypoxia or treatment, providing more information than static measurements of glucose uptake, lactate, lipid peroxidation or antioxidant enzymes. Microbiome studies could test whether the tumor alters gut microbial communities or whether microbial metabolites influence systemic inflammation and treatment response. Because the model induces endocrine and stress responses, neural and neuroimmune signaling may also be examined experimentally.

Manipulating light–dark cycles, feeding times and treatment schedules could support chronobiology studies of tumor growth, immune activity and therapeutic sensitivity, although evidence specific to Ehrlich carcinoma remains limited. The review concludes that modernizing Ehrlich carcinoma does not require the model to become a substitute for clinically representative systems. Organoids and patient-derived xenografts can retain patient-specific tumor features; genetically engineered mouse models can define genetic drivers; and EC/EAC provides a comparatively accessible, immunocompetent environment in which growth, immunity, metabolism and treatment effects can be observed together.

A practical discovery-to-validation pathway would move from multi-omics and small-RNA profiling to candidate RISC-regulated networks, then to CRISPR or pharmacological perturbation, assessment of tumor, immune and treatment phenotypes, and validation in breast cancer cell systems, organoids, patient-derived xenografts or other appropriate models. Important limits remain: species-specific immune and stromal differences, limited heterogeneity, passage history, the ascitic phenotype, experimentally introduced established cells and the inability to model early carcinogenesis or patient-specific responses. The value of EC/EAC therefore lies in identifying mechanisms robust enough to justify validation across complementary models, not in treating its findings as direct evidence of human breast cancer biology.

Subject of Research: Review of methods for modernizing Ehrlich carcinoma as a complementary in vivo model of tumor and host biology

Article Title: Revisiting Ehrlich carcinoma in the era of precision oncology: bridging classical models with modern systems biology

Article References: Manjunath, V., Nayak, R. R., Bhujanga, A. K., Ramesh, A. M., & Santhekadur, P. K. (2026). Revisiting Ehrlich carcinoma in the era of precision oncology: bridging classical models with modern systems biology. Medical Oncology, 43(11), Article 342. https://doi.org/10.1007/s12032-026-03452-x

Image Credits: AI Generated

DOI: 10.1007/s12032-026-03452-x

Keywords: Ehrlich carcinoma, Ehrlich ascites carcinoma, systems biology, precision oncology, RNA-induced silencing complex, microRNA regulation, multi-omics, single-cell profiling, spatial transcriptomics, CRISPR functional genomics, tumor microenvironment, murine cancer models

The review, led by Dong Yu and Jin Shi of the University Children’s Hospital Basel and the University of Basel, together with colleagues including bone tumor pathologist Daniel Baumhoer and pediatric surgeon Andreas H. Krieg, synthesizes evidence that CAFs are not passive scaffolding within the tumor microenvironment but active engineers of immune escape. By depositing and stiffening extracellular matrix, secreting immunosuppressive cytokines and chemokines, dispatching exosomes loaded with regulatory cargo, and competing with immune cells for scarce metabolic resources, these fibroblasts create what the authors describe as a treatment-refractory niche. The result is a tumor that excludes cytotoxic T cells, reprograms myeloid cells toward suppressive states, and shrugs off both chemotherapy and the immunotherapies that have transformed other cancers.

The mechanical dimension of this exclusion is perhaps the most striking. CAFs in osteosarcoma produce dense collagen-rich matrix that physically walls off tumor tissue from infiltrating lymphocytes, a phenomenon known as immune exclusion. Matrix deposition and stiffening do more than create a barrier; they alter mechanotransduction signaling within tumor cells, promote the activation of survival pathways such as focal adhesion kinase signaling, and impede the delivery of chemotherapeutic agents to their targets. In a bone tumor that already presents a challenging anatomical environment, this stromal hardening compounds the difficulty of achieving effective drug penetration and immune surveillance simultaneously.

Beyond the physical barrier, the review details how CAFs wage chemical warfare on the immune system. Through cytokine and chemokine signaling, these fibroblasts recruit and polarize immune cells in ways that favor tumor progression, drawing in myeloid cells and converting them into immunosuppressive allies while actively excluding or exhausting T cells that might otherwise recognize and destroy malignant osteoblasts. Exosome-mediated communication adds another layer of sophistication: CAF-derived vesicles carry microRNAs, proteins, and metabolites that can reprogram recipient cells, spreading immunosuppressive instructions throughout the microenvironment like molecular memos.

Metabolic competition represents a fourth and increasingly appreciated mechanism. Rapidly proliferating tumors and their stromal accomplices consume glucose, amino acids such as glutamine and tryptophan, and other nutrients at ferocious rates. When CAFs monopolize these resources, infiltrating T cells are starved of the fuel they need for effector function, effectively disarming them even if they manage to penetrate the tumor. The review emphasizes that these four mechanisms—matrix remodeling, soluble signaling, exosomal communication, and metabolic hijacking—do not operate in isolation but form an integrated program of immune exclusion that reinforces itself at every level.

What distinguishes this review from earlier treatments of the topic is its effort to organize a fragmented literature into an evidence-stratified translational framework, and its attention to the distinct stromal contexts of primary tumors versus pulmonary metastases. Osteosarcoma spreads overwhelmingly to the lungs, and the microenvironment of a lung metastasis differs substantially from that of a primary bone lesion. The authors argue that therapeutic strategies must account for these site-specific differences, since a CAF-targeting approach validated only in primary tumor models may fail to translate to the metastatic setting where most treatment failures occur.

The arrival of single-cell RNA sequencing and spatial profiling technologies has begun to resolve CAF biology at unprecedented resolution. The review highlights emerging CAF states and stromal-immune interaction programs identified by these high-dimensional approaches, revealing that cancer-associated fibroblasts are not a uniform population but a constellation of functionally distinct subtypes. Some CAF states correlate strongly with T-cell exclusion, others with myeloid reprogramming, and still others with chemotherapy resistance and diminished immunotherapy response. This heterogeneity carries a sobering implication: any therapeutic strategy that targets only one CAF subset may leave the others free to sustain immune escape, arguing for combination approaches informed by detailed stromal mapping of individual tumors.

On the therapeutic front, the authors evaluate several promising directions while carefully calibrating expectations. CAF normalization—reprogramming activated fibroblasts back toward a quiescent state rather than killing them outright—has emerged as an attractive strategy because it preserves the structural functions of stromal cells while stripping away their tumor-promoting behaviors. Matrix-targeted interventions aim to soften or degrade the physical barrier, potentially improving both drug delivery and immune infiltration. Local delivery strategies, which concentrate stromal-modulating agents at the tumor site, could mitigate the systemic toxicities that have plagued broader anti-stromal approaches. Among specific molecular targets, the review singles out NADPH oxidase 4 inhibition, focal adhesion kinase-related stromal targeting, and sequence-based chemoimmunotherapy as key translational directions, each of which requires further validation for delivery feasibility, safety, and biomarker-guided patient selection.

Perhaps the review’s most important message is one of strategic realism. The authors conclude that current evidence supports CAF-directed intervention in osteosarcoma primarily as a microenvironment-modulating and treatment-sensitizing strategy rather than as a stand-alone cytotoxic approach. In other words, targeting fibroblasts is unlikely to cure osteosarcoma by itself, but it may render tumors newly vulnerable to the chemotherapy, surgery, and immunotherapy that form the backbone of existing care. This framing reframes CAF biology from a niche academic interest into a potential force multiplier for the entire therapeutic arsenal.

The path to the clinic, the authors caution, runs through several non-negotiable checkpoints. Clinical translation will require osteosarcoma-specific validation in bone-relevant and immunocompetent models, since much of the existing evidence derives from systems that poorly recapitulate the human disease. It will also depend on the development of multiplex CAF biomarker panels compatible with formalin-fixed, paraffin-embedded tissue—the standard archival material available in pathology departments worldwide—so that patient stratification can be performed on realistic clinical samples. Finally, rational treatment-sequencing strategies must be designed that integrate stromal normalization with chemotherapy, surgery, and immunotherapy in the correct order, since an improperly timed stromal intervention could theoretically undermine rather than enhance conventional treatment. For a disease that has seen so little progress for so long, the fibroblast-centered vision offered by the Basel-led team represents neither a miracle cure nor a false dawn, but a disciplined roadmap for turning the tumor’s own architecture against it.

Subject of Research: Cancer-associated fibroblast-mediated immune exclusion and therapy resistance in osteosarcoma

Article Title: CAF-mediated immune exclusion in osteosarcoma: mechanisms, translational vulnerabilities, and therapeutic strategies

Article References: Yu, D., Shi, J., Gros, S., Loboda, F., Baumhoer, D., & Krieg, A. H. (2026). CAF-mediated immune exclusion in osteosarcoma: mechanisms, translational vulnerabilities, and therapeutic strategies. Journal of Translational Medicine. https://doi.org/10.1186/s12967-026-08913-5

Image Credits: AI Generated

DOI: 10.1186/s12967-026-08913-5

Keywords: osteosarcoma, cancer-associated fibroblasts, tumor microenvironment, immune exclusion, immunotherapy, chemotherapy resistance, extracellular matrix, single-cell profiling, NOX4 inhibition, focal adhesion kinase, chimeric antigen receptor T cells, pediatric oncology

The study, published in Cancer Immunology Research, a journal of the American Association for Cancer Research, tackles a question that immunologists have rarely been able to address directly in human tissue: does the way a T cell generates and uses energy determine whether it mounts an effective attack or slides into exhaustion? Exhaustion is a state in which a cell, activated too long and too continuously, stops responding to the threats it was designed to destroy. Checkpoint immunotherapy, such as antibodies against the PD-1 receptor, releases one of the brakes holding those cells back. For some patients the effect is dramatic; for many others it fails, and the reasons have remained stubbornly unclear.

Metabolism has long seemed a plausible place to look for answers. An immune cell’s capacity to act — to proliferate, to produce inflammatory signals, to kill tumor cells — is constrained by how it generates energy and building blocks. But probing that relationship in human tumors has been technically formidable. The standard laboratory method for measuring cellular metabolism requires a large, pure population of a single cell type, something that is nearly impossible to obtain from a biopsy. As first author Sujeetha A. Rajakumar, Ph.D., a former research associate in the Department of Otolaryngology–Head and Neck Surgery at Johns Hopkins Medicine, explains, what arrives from the clinic is a mixture, there is not much of it, and the cells researchers most want to study are often the rarest. Most of what the field knows about immune cell metabolism has therefore come from mouse tissue and cells grown in dishes, systems that do not always faithfully reflect what happens inside a patient.

The Johns Hopkins team circumvented this bottleneck by measuring each cell’s metabolic machinery alongside the surface markers that identify it. This approach allowed them to read three things from a single cell simultaneously: which cell type it is, what functional state it is in, and what metabolic profile it uses. They applied the method to several populations of tumor-infiltrating immune cells, including mucosal-associated invariant T (MAIT) cells, conventional CD8+ T cells, and innate lymphoid cells (ILCs). Because the technique works on scarce and mixed samples, it opened a window onto metabolic states that had previously been invisible in human tumor tissue.

The tumor samples came from patients enrolled in two phase II clinical trials at Johns Hopkins Medicine in which immunotherapy was administered before surgery. Participants received either the anti-PD-1 antibody nivolumab alone or nivolumab combined with an antibody against interleukin-8, a signaling protein that recruits immune cells to sites of inflammation and infection. Tissue was collected before immunotherapy began and again four weeks later at the time of surgery, giving the investigators a rare opportunity to observe how the immune and metabolic states of individual cells changed within the same patients over the course of treatment.

Three findings stood out. First, the team identified a population of T cells within these tumors that proved to be metabolically fitter and less exhausted than their neighbors, suggesting that not all tumor-infiltrating lymphocytes are equally depleted and that metabolic state tracks closely with function. Second, the more exhausted cells showed elevated levels of the enzyme glucose-6-phosphate dehydrogenase, or G6PD, the rate-limiting enzyme of a metabolic pathway those cells appear to rely on — making it a possible point of intervention. Third, a subset of innate lymphoid cells carried a metabolic profile associated with immune suppression, raising the possibility that these cells may actively pose an obstacle to checkpoint therapy rather than merely failing to help it.

To test whether the exhausted cells truly depend on the G6PD pathway, the researchers turned to laboratory cultures of tumor-infiltrating CD8+ T cells from a separate group of untreated patients. They sorted the cells according to their expression of CD39, a protein that can contribute to immunosuppression by limiting the activation of T cells. The cultures were then treated with a G6PD inhibitor, with an anti-PD-1 antibody, with both, or with neither. The combination treatment produced the largest gene expression changes in the most exhausted cells and increased their secretion of CD27, a marker of T-cell activation. In other words, the cells that seemed least reachable by conventional immunotherapy were the ones that changed the most when the metabolic pathway was blocked alongside checkpoint blockade.

Senior author Martin Alphonse, Ph.D., an assistant professor of dermatology at the Johns Hopkins University School of Medicine, frames the work around a deceptively simple question: take a piece of head and neck tumor tissue and you will find immune cells inside it whose sole purpose is to recognize something abnormal and destroy it — so what has happened to them? The answer emerging from this study is that part of what has happened is metabolic. Exhausted cells appear to have rewired their energy production in a way that can be mapped, and at least one node of that rewiring can be targeted in the laboratory to partially restore function. Rajakumar notes that when the pathway was blocked alongside checkpoint inhibitor treatment, the cells expected to be least reachable changed the most and became reactivated — evidence, she says, that the pathway is worth pursuing.

The clinical context makes the work consequential. Head and neck squamous cell carcinoma, which arises from the cells lining the mouth, throat and voicebox, is the seventh most common cancer worldwide, with roughly 890,000 new cases each year. With checkpoint inhibitors helping fewer than a quarter of these patients, any strategy that could expand the fraction of responders would address a major unmet need. Growing evidence has suggested that metabolic reprogramming influences whether a T cell mounts an effective response or becomes exhausted, but this study is among the relatively few to examine that link directly in human tumor tissue rather than in animal models or cell lines, and to do so across multiple immune cell types at single-cell resolution.

The researchers and their collaborators are careful to stress what the findings are and what they are not. Blocking G6PD in laboratory cultures reactivated exhausted cells, but no patient in the trials received a G6PD inhibitor, and the approach should not be considered a treatment itself. Alphonse emphasizes that these findings need confirmation in larger patient groups before anything can be built on them. The next steps, he says, are to reproduce the results in independent cohorts and to test whether interfering with this metabolic step has any effect in a living system, not just in a dish. Additional co-authors are Namya Nanda, Chloe Kim, Dustin Dikeman, Tanguy Y. Seiwert, Zubair Khan and Sewon Kang, all affiliated with Johns Hopkins Medicine. Study co-author Carole Fakhry, M.D., M.P.H., senior associate dean for clinical affairs at Johns Hopkins, underscores that such interdisciplinary, collaborative studies are critical to understanding how to make therapies more effective in the future, leveraging the translational capabilities of clinical trials to generate insights that laboratory work alone cannot provide. The work was supported by the Johns Hopkins Department of Dermatology, a Career Development Award from the Dermatology Foundation, the Department of Otolaryngology–Head and Neck Surgery, and the Bloomberg~Kimmel Institute for Cancer Immunotherapy. Alphonse and Rajakumar are inventors on two provisional patent applications related to the work, assigned to The Johns Hopkins University, which manages these relationships under its conflict-of-interest policies.

Subject of Research: Immunometabolic profiling of exhausted tumor-infiltrating T cells in head and neck squamous cell carcinoma

Article Title: Johns Hopkins investigators identify a metabolic weak point in exhausted immune cells in head and neck cancer

Article References: Johns Hopkins investigators identify a metabolic weak point in exhausted immune cells in head and neck cancer. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: head and neck cancer, T cell exhaustion, immunotherapy, checkpoint inhibitors, G6PD, tumor metabolism, CD8+ T cells, innate lymphoid cells, MAIT cells, nivolumab, single-cell profiling, Cancer Immunology Research